Javascript must be enabled to continue!
Treatment of Neurogenic Detrusor Overactivity with Botulinum Toxin A: The First Seven Years
View through CrossRef
<i>Introduction:</i> This retrospective study describes the results of botulinum toxin A detrusor injections following a fixed protocol in 216 patients with untreatable neurogenic detrusor overactivity and incontinence. A comparison is made between the two preparations currently available, and the efficacy of multiple treatments is studied. <i>Patients and Methods:</i> Botox® 300 MU (mouse units) or Dysport® 750 MU were injected into the detrusor wall in 365 sessions in 216 patients. The average age of the 144 men and 72 women was 32.3 years. Patients were investigated before treatment and at 6 weeks and 6 months after treatment. Maximal detrusor pressure, detrusor compliance, reflex volume and cystometric capacity were recorded. Use of anticholinergics and patient satisfaction were ascertained from questionnaires. Appropriate statistics were applied. <i>Results:</i> All urodynamic parameters improved. The use of anticholinergics decreased substantially. No differences were noted between the two preparations. The incontinence situation improved markedly. The effect of the treatment was noted after about 2 weeks and lasted for about 9 months. <i>Conclusions:</i> Botulinum toxin A treatment in neurogenic detrusor overactivity patients is effective, long-lasting and repeatable. The treatment is minimally invasive and might be considered as an alternative to high-dosage anticholinergic medication.
Title: Treatment of Neurogenic Detrusor Overactivity with Botulinum Toxin A: The First Seven Years
Description:
<i>Introduction:</i> This retrospective study describes the results of botulinum toxin A detrusor injections following a fixed protocol in 216 patients with untreatable neurogenic detrusor overactivity and incontinence.
A comparison is made between the two preparations currently available, and the efficacy of multiple treatments is studied.
<i>Patients and Methods:</i> Botox® 300 MU (mouse units) or Dysport® 750 MU were injected into the detrusor wall in 365 sessions in 216 patients.
The average age of the 144 men and 72 women was 32.
3 years.
Patients were investigated before treatment and at 6 weeks and 6 months after treatment.
Maximal detrusor pressure, detrusor compliance, reflex volume and cystometric capacity were recorded.
Use of anticholinergics and patient satisfaction were ascertained from questionnaires.
Appropriate statistics were applied.
<i>Results:</i> All urodynamic parameters improved.
The use of anticholinergics decreased substantially.
No differences were noted between the two preparations.
The incontinence situation improved markedly.
The effect of the treatment was noted after about 2 weeks and lasted for about 9 months.
<i>Conclusions:</i> Botulinum toxin A treatment in neurogenic detrusor overactivity patients is effective, long-lasting and repeatable.
The treatment is minimally invasive and might be considered as an alternative to high-dosage anticholinergic medication.
Related Results
Pain during ice water test distinguishes clinical bladder hypersensitivity from overactivity disorders
Pain during ice water test distinguishes clinical bladder hypersensitivity from overactivity disorders
Abstract
Background
The Bladder cooling reflex (BCR) i.e. uninhibited detrusor contractions evoked by intravesical instillation of cold saline, i...
Botulinum Toxin Type A in Neurogenic Overactive Bladder Dysfunction in Patients with Multiple Sclerosis
Botulinum Toxin Type A in Neurogenic Overactive Bladder Dysfunction in Patients with Multiple Sclerosis
Introduction Lower Urinary tract symptoms are common in patients with multiple sclerosis (MS) and have a negative influence on the quality of life (QoL). Detrusor overactivity is t...
Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Introduction This article reviews the mechanism of action of botulinum toxin and provides an overview of its use in hand disorders relevant to hand therapy such as hyperhidrosis, s...
Public perception and knowledge toward the non-cosmetic use of botulinum toxin in dermatology practices
Public perception and knowledge toward the non-cosmetic use of botulinum toxin in dermatology practices
Background: While botulinum toxin is widely known for its cosmetic applications, its therapeutic potential in dermatology remains under-recognized by the general public. This study...
Antiarrhythmic properties of Botulinum toxin A: in vitro studies on human and rat cardiomyocytes
Antiarrhythmic properties of Botulinum toxin A: in vitro studies on human and rat cardiomyocytes
Abstract
Botulinum toxin A is a well-known neurotransmitter inhibitor with a wide range of applications in modern medicine. In recent years, botulinum toxin preparations ha...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract
Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
Botulinum toxin A and chronic back pain: a randomized, double‐blinded study. (Walter Reed Army Medical Center, Washington, DC) Neurology. 2001;56:1290–1293.
Botulinum toxin A and chronic back pain: a randomized, double‐blinded study. (Walter Reed Army Medical Center, Washington, DC) Neurology. 2001;56:1290–1293.
This study investigated the efficacy of botulinum toxin A in chronic low back pain and associated disabilities. Thirty‐one consecutive patients with chronic low back pain who met t...
Observing Adverse Effects of Botulinum Toxin Injection in Cervical Dystonia Pateints
Observing Adverse Effects of Botulinum Toxin Injection in Cervical Dystonia Pateints
Background: Cervical dystonia is the most common adult onset focal dystonias and botulinum toxin injection is an effective treatment for this condition.
Objective: The objective o...

